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Abstract
Objectives: The aim of this study was to investigate the prevalence of cardiac manifestations and their predictive factors
in Moroccan patients with spondyloarthritis (SpA).
Methods: We have conducted a cross-sectional study over four months at the Department of Rheumatology in
Mohammed VI University Hospital of Oujda, Morocco. All SpA patients fulﬁlled the 2009 Assessment SpondyloArthritis international Society (ASAS) criteria. Every patient had a cardiac check up including clinical examination, 12-lead
electrocardiogram (ECG) and transthoracic echocardiography (TTE). Multiple logistic regression was used to analyze the
associated factors with cardiac manifestations.
Results: We included 64 men and 30 women with a mean age of 37.32 ± 12.65 years old. The mean disease duration was
10.60 ± 7.61 years. Patients had a mean Ankylosing Spondylitis Disease Activity Score (ASDAS) CRP of 2.25 ± 1.38, a
mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of 2.88 ± 2.26 and a mean Bath Ankylosing
Spondylitis Functional Index (BASFI) of 33.52 ± 30.49. Traditional cardiovascular risk factors (CVRF) included dyslipidemia in 14.9%, hypertension in 9.6% and type 2 diabetes in 7.4% of the cases. Eight patients (8.5%) smoked and 3
patients (3.2%) used alcohol whereas 20 patients (21.3%) had a history of smoking and 5 patients (6.3%) a history of
alcohol. Cardiac manifestations were found in 12 patients (13.3%): 3.3% had aortic regurgitation (AR), 1.1% had aortic
dilatation, 1.1% had aortic valve thickening (AVT), 2.2% had mitral thickening, 1.1% had mitral regurgitation (MR), 1.1%
had mitral stenosis (MS), 3.3 had pericarditis and 2.2% had complete right bundle branch block (RBBB). In multivariate
analysis, cardiac involvement was signiﬁcantly associated with extra-articular manifestations (OR ¼ 6.05; 95% CI: 1.19730.607, p ¼ 0.029).
Conclusion: Based on these results, cardiac involvement was common and associated with the severity of the disease;
hence, early detection of cardiac abnormalities and targeted treatment strategies of SpA and comorbidities are necessary
to control the systemic inﬂammation and improve the excess of cardiovascular mortality in this group of patients.
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1. Introduction

S

pondyloarthritis (SpA) is a heterogenic group
of 5 immune-mediated inﬂammatory diseases:
Ankylosing spondylitis (AS), Reactive arthritis
(ReA), arthritis associated with inﬂammatory
bowel disease (IBD), Psoriatic arthritis (PsA), and
undifferentiated spondyloarthritis (uSpA) [1].
Its prevalence ranges widely from 0.03% in the

Asia Paciﬁc League of Associations for Rheumatology (APLAR) region to 2.5% in Alaska and
Russia, depending on the genetic background,
especially human leucocyte antigen B27 (HLAB27) and geographic distribution of ethnic groups
[2, 3]. If we consider SpA as a disease entity, the
sex-ratio is nearly 1. It often affects young adults
with a peak age of onset between 20 and 30 years
old [1, 4].
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SpA is a complex polygenic disease; its pathogenesis remains a rheumatology enigma. It is triggered by environmental and genetic risk factors
(HLA-B27, interleukin-23 (IL-23), endoplasmic reticulum aminopeptidase 1 (ERAP-1), microbiota
changes and biomechanical stress) which lead to the
activation of autoimmunity and chronic inﬂammation [1, 5, 6]. The mean SpA target is enthesis, but
the synovial tissue can also be affected along with
other extra-articular tissues such as the cardiovascular system [6, 7].
Cardiac involvement is a well recognized
complication of SpA. It is common and associated
with an increased mortality rate in this population
when compared to the general population [6-10].
The spectrum of disease is large; it includes valvular
heart disease (VHD), conduction disturbances and
cardiomyopathy. These anomalies that are usually
linked to comorbidities and treatments can also be
induced by chronic inﬂammation [8, 11, 12].
If not treated, the chronic inﬂammation leads to
ﬁbrosis proliferation that affects the aortic root and
valve, and could expand to the interventricular
septum causing the dilatation of the aortic root,
valve thickening and regurgitation. Occasionally,
interventricular septum causes high-grade atrioventricular block (AVB) that represents the second
highest prevalent cardiac manifestation after the AR
in SpA patients [6, 7, 11, 13]. In 1930, the high
prevalence of aortitis rates increasing among patients with SpA was described for the ﬁrst time [14].
Quite recently, considerable attention is paid to the
prevalence and prognostic value of VHD and the
use of the pacemaker.
In this study, our purpose was to investigate the
prevalence of cardiac manifestations and analyze
their predictive factors in a Moroccan population of
SpA patients.

2. Materials and methods
2.1. Study design
This cross-sectional study was carried out in the
Rheumatology department of Mohamed VI University Hospital in Oujda, Morocco. Patients with
spondyloarthritis (SpA) diagnosis visiting our care
unit, from September 2017 to December 2017 were
enrolled. We studied the cases of ninety-four patients. All patients fulﬁlled the 2009 Assessment
SpondyloArthritis international society (ASAS)
classiﬁcation criteria for axial and peripheral SpA.
Patients with history of infective endocarditis,
neoplasm, or other chronic inﬂammatory rheumatism were excluded from the enrollment. Written

Abbreviation list
AR
AS
AVB
AVT
BBB
CRP
CVRF
ESR
HLA
MR
MS
MVA
SpA
VHD

Aortic regurgitation
Ankylosing Spondylitis
Atrioventricular block
Aortic valve thickening
Bundle branch block
C-reactive protein
Cardiovascular risk factors
Erythrocyte sedimentation rate
Human leucocyte antigen
Mitral regurgitation
Mitral stenosis
mitral valve area
Spondyloarthritis
Valvular heart disease

informed consent was approved by the ethical
committee and obtained from all subjects.
2.2. Data collection
Data-collection forms involved demographic
data, age at disease onset, disease duration, history
of peripheral joint surgery, clinical characteristics
(axial involvement, peripheral arthritis, enthesitis),
SpA-related comorbidities (psoriasis, uveitis, inﬂammatory bowel disease), disease severity reﬂected by the presence of axial involvement,
coxitis, an anterior atlanto-axial subluxation, and
extra-articular manifestations (EAMs) including
pulmonary involvement, Sjogren syndrome, and
renal amyloidosis. Traditional cardiovascular risk
factors (CVRF) and history of cardiovascular disease (CVD) which is composed of ischemic heart
disease, stroke and cerebrovascular disease were
collected.
All participants underwent a rheumatological
evaluation including swollen and tender joints
counts and clinical enthesitis count. Pain intensity
and fatigue were assessed by visual analog scale
(VAS; 0-10). Anthropometric measurements and
blood pressure were taken.
Every patient had a cardiac check up with
research of clinical cardiac manifestations. A standard resting 12-lead ECG was recorded to analyze
the rhythm and conduction disturbances (AVB of
ﬁrst to third degree, right bundle branch block
(RBBB) or left bundle branch block (LBBB)). Transthoracic echocardiography (TTE) was performed for
the diagnosis of cardiac abnormalities including
those of the valve (regurgitation, thickening, stenosis, and dilatation) and pericardial effusion. Valve
regurgitation and stenosis were assessed using
semiquantitative methods to be categorized into

grade I (mild), grade II (moderate), and grade III
(severe). Valve thickening was deﬁned as focal or
diffuse leaﬂet thickening superior to 2 mm for the
aortic valve and 3 mm for the mitral valve.
Ascending aorta dilatation was deﬁned as >41 mm
for the sinus or >35 mm for the annulus. Moreover,
pericardial effusion was characterized as mild
(<10 mm of echo-free space in diastole), moderate
(10-20 mm), or large (>20 mm).
A blood sample with analysis including C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR),
HLA-B27 status, and other standard hematological
assessments were undertaken.
Disease activity was assessed with the Bath
Ankylosing Spondylitis Disease Activity Index
(BASDAI; 1-10) and the Ankylosing Spondylitis
Disease Activity Score based on CRP and ESR
(ASDAS-CRP, ASDAS ESR). A BASDAI score  of 4
on a 10-point scale was accepted to designate active
disease. The ASDAS scores were used to classify
disease activity as inactivity (<1.3), low (1.3-2.1),
high (2.1-3.5) or very high (>3.5). Functional status
was evaluated by the Bath Ankylosing Spondylitis
Functional Index (BASFI; 1-100).
2.3. Statistical analysis
Statistical analysis was performed using the IBM
SPSS Statistics version 20 software. Descriptive
statistics encompass numbers (percentages) for
categorical variables and means (standard deviation) or medians for continuous variables. Chisquare test or Fisher's exact test were used to
compare qualitative variables and the Student's ttest was performed for quantitative variables. A
multivariate logistic regression analysis was performed to determine the predictive factors of cardiac
manifestations. The level of signiﬁcance was
accepted as p value < 0.05.

3. Results
The socio-demographic and clinical characteristics of the study population are shown in Table 1.
Cardiac manifestations were found in 12 patients
(13.3%) in which 3.3% had aortic regurgitation (AR)
(Fig. 1). Grade 1 AR and grade 2 AR were observed
in 2 patients and one other patient respectively.
1.1% of the population had ascending aortic dilatation (47 mm) and 1.1% had aortic valve thickening
(AVT). Mitral thickening was seen in 2.2% in which
one patient had a focal thickening with mitral valve
area (MVA) measured by pressure half-time of
5.2 cm2 and a peak gradient of 3.2 mmHg.
Furthermore, 1.1% of the patients had mitral

Table 1. Clinical data in 94 patients with SpA.
Clinicopathological and therapeutic patterns
Demographic characteristics
Sex (F/M) (number, %)
Age, years (mean, SD)
SpA characteristics
Disease duration, years (mean, SD)
Axial involvement (number, %)
Peripheral arthritis (number, %)
Enthesitis (number, %)
EAMs (number, %)
Uveitis (number, %)
Psoriasis (number, %)
IBD (number, %)
Coxitis (number, %)
aAAS (number, %)
CRP, mg/l (median, range)
ESR, mm/h (median, range)
BASDAI (0-10) (mean, SD)
ASDAS CRP (mean, SD)
ASDAS VS (mean, SD)
BASFI (0-100) (mean, SD)
Traditional CVRF (number, %)
Hypertension (SBP140 and/or DBP 90
and/or antihypertensive drugs)
Diabetes type 2
Dyslipidemia
Obesity (>30 BMI)
Current smoking
Past smoking
Current alcohol consumption
Past alcohol consumption
History of CVD (number, %)
Cardiac manifestations (number, %)
SpA-related medications (number, %)
DMARDs
TNF inhibitors
Methotrexate
Sulfasalazine
Non steroidal anti-inﬂammatory drugs

30(31.9)/64(68.1)
37.32 ± 12.65
10.60 ± 7.61
71 (75.5)
41 (43.6)
69 (73.4)
49 (52.1)
13 (13.8)
14 (14.9)
11/17 (11.7)
39 (42.9)
2 (2.1)
8.5 (0-197)
16 (1-131)
2.88 ± 2.26
2.25 ± 1.38
2.19 ± 1.23
33.52 ± 30.49
9 (9.6)
7 (7.4)
14 (14.9)
11 (11.7)
8 (8.5)
20 (21.3)
3 (3.2)
5 (5.3)
0 (0.0)
12 (13.3)

36
30
23
45

(38.3)
(31.9)
(24.5)
(47.9)

aAAS: anterior atlanto-axial subluxation, ASDAS: Ankylosing
Spondylitis Disease Activity Score, BASDAI: Bath Ankylosing
Spondylitis Disease Activity Index, BASFI: Bath Ankylosing
Spondylitis Functional Index, CVD: cardiovascular disease,
CVRF: cardiovascular risk factors, DMARDs: Disease-modifying
antirheumatic drugs, EAMs: extra-articular manifestations, ESR:
erythrocyte sedimentation rate, IBD: inﬂammatory bowel disease,
SD: standard deviation.

regurgitation (MR) classiﬁed as mild in grading
mitral regurgitation severity, and 1.1% had mitral
stenosis (MS) (the MVA measured by planimetry
and doppler was >1.5 cm2) (Fig. 2). 3.3% of the
population had pericarditis in which one patient
had moderate pericardial effusion (Fig. 3) and two
had mild disease. Additionally, 2.2% of the population had complete right bundle branch block
(RBBB).
In comparison with the group without cardiac
involvement (Table 2), the presence of cardiac abnormalities was signiﬁcantly associated with severe
SpA: EAMs (p ¼ 0.04), an anterior atlanto-axial
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Fig. 1. Transthoracic echocardiography of a 37-years-old woman with severe spondyloarthritis. (A) The parasternal short-axis view demonstrating a
mitral stenosis (mitral valve areas > 1.5 cm2). (B) A four-chamber view revealing aortic regurgitation (peak gradient ¼ 53.60 mmHg).

subluxation (p ¼ 0.01) and axial involvement
(p ¼ 0.037). Concerning the type of cardiac manifestations, patients with VHD had longer disease
duration (12.00 ± 8.71 years) compared to those
without VHD; however, this difference was not
statistically signiﬁcant. EAMs were frequent among
the group with cardiac involvement, but only VHD
was signiﬁcantly associated with EAMs (p ¼ 0.008).
Patients with pericarditis and conduction disorders
had higher disease activity and statistically signiﬁcantly higher ESR (p ¼ 0.004). Moreover, no significant association between conventional CVRF and
cardiac involvement was found. In multivariate
analysis, cardiac involvement was the only predictive factor of EAMs (OR ¼ 6.05; 95% CI: 1.197-30.607,
p ¼ 0.029).

4. Discussion
In the present study, the pooled prevalence of
cardiac manifestations reached 13.3%. The most
common abnormality was VHD (7.8%) followed by

Fig. 2. The transthoracic echocardiography (parasternal long-axis view)
of a 62-years-old woman with psoriatic arthritis revealing mild thickened aortic and mitral valve.

pericarditis (3.3%) and conduction defects (2.2%).
This was within the range described in former
studies; it widely ranged from 2% [15, 16] to 14% [18]
and it can reach up to 82% [18, 19] when compared
with the normal population. Kinsella et al. [17] noted
that 14% of 97 patients with AS had cardiovascular
anomalies. Another contemporary study by Sukenik
et al. [20] showed that 42.5% of 40 patients with AS
had cardiac manifestations. However, the results of
other studies are still conﬂicting. In fact, a recent
study by Sorouch et al. [21] demonstrated that patients having AS does not inﬂuence heart
involvement.
The most commonly recognized cardiac manifestation of SpA is aortic valve disease, which is usually
restricted to the ascending aorta and aortic arch, and
includes aortic regurgitation (AR), aortic valve
thickening (AVT) and aortitis [6]. Its prevalence increases with age and is especially related to the
disease duration [22-24]. In our study, the prevalence of aortic involvements was distributed as follows: 3 (3.3%) had AR, 1 (1.1%) had aortic dilatation
and 1 (1.1%) had AVT. These results were in

Fig. 3. The transthoracic echocardiography (in the apical four-chamber
view) of a 38-years-old woman with spondyloarthritis revealing echofree space of 10 mm located laterally to the right atrium, suggestive of
moderate pericardial effusion.

Table 2. Comparison between SpA patients with and without cardiac manifestations.

SpA characteristics
Disease duration, years (mean, SD)
Axial involvement (number, %)
aAAS (number, %)
Coxitis (number, %)
Extra-articular manifestations (number, %)
Comorbidities (psoriasis and others) (number, %)
CRP, mg/l (median, range)
ESR, mm/h (median, range)
Traditional CVRF (number, %)
Hypertension (SBP140 and/or DBP 90
and/or antihypertensive drugs)
Diabetes type 2
Dyslipidemia
Obesity (>30BMI)
Current smoking
Current alcohol consumption

Patients with cardiac
involvement (n ¼ 12)

Patients without cardiac
involvement (n ¼ 82)

p value

11.50 ± 7.14
6 (50)
1 (8.3)
3 (30)
4 (33.3)
10 (83.3)
6.5 (0-110)
35 (1-131)

10.52 ± 7.79
61 (78.2)
0 (0.0)
34 (44.2)
9 (11.5)
37 (47.4)
8.5 (0-197)
16 (1-124)

0.68
0.037
0.01
0.39
0.04
0.02
0.57
<0.001

3 (25)

6 (7.7)

0.06

2
3
0
0
0

5 (6.4)
11 (14.1)
11 (14.1)
8 (10.3)
2 (2.6)

0.21
0.33
0.16
0.24
0.57

(16.7)
(25)
(0.0)
(0.0)
(0.0)

aAAS: anterior atlanto-axial subluxation, CRP: C-reactive protein, CVRF: cardiovascular risk factors, ESR: erythrocyte sedimentation
rate, SD: standard deviation.

agreement with previous studies which demonstrated an increased prevalence of SpA-related AR,
from 1.7% in a study by Bernstein et al. in 1951 to
10% in an echocardiography survey of 24 AS patients conducted by Graham et al. in 1958 [16, 17].
The average rate of AR in longstanding AS was 6.9%
between 1970 and 1983 and increased to 10.8%
(going from 1.8 to 16%) in the reviewed literature
from 1987 to 2005. This ﬁnding was explained by the
continuous sensitivity and speciﬁcity enhancement
of cardiology techniques [18, 25, 26]. In a cohort of 42
327 age-matched patients, the prevalence of aortic
and mitral valve diseases increased from less than
4% in those aged 65 to 69 years old to 20% in those
aged 80 years old or older when compared with
patients without SpA [19]. This study also reported
that the prevalence of aortic valve surgeries was
slightly higher within this population group
compared with the control group [19]. Bengtsson
et al. reported in their cohort 1.2% of AR among a
population where only 27% were older than 60 years
[27]. The results showed that the patients’ age
inﬂuenced the results since these affections are
usually rare among the young population, while
being very common among elderly patients. In
early AS, a 4% prevalence of aortic disease has been
reported [28].
Mitral valve disease is known to occur among SpA
patients but remains less common than aortic valve
disease; its manifestations can go from thickening to
the severe regurgitation needing valve replacement.
Its prevalence in SpA patients increases with age
like the prevalence of aortic valve disease [16, 19]. In
our study, 2.2% of patients had mitral thickening,

1.1% patients had mitral regurgitation (MR) and
1.1% had mitral stenosis (MS). Based on the ﬁndings
in literature, mitral valve disease is more prevalent
in longstanding AS (going from 32 to 40%) [18, 25].
In a study of homogeneous population of 100 male
AS patients, the prevalence of MR was 29% [24, 25].
In 2018, in comparison with patients without SpA,
Ward et al. found in their cohort a slightly higher
risk of mitral valve disease in all groups of age [19].
In case series, echocardiographic evidence of MR
was described to go from 5% to 74% [18, 19, 24, 26].
Conduction disorders as bundle-branch blocks
(BBB), atrioventricular blocks (AVB), and intraventricular blocks have been frequently observed in
patients with SpA, especially among those with
associated valvular involvement and may require a
pacemaker [19, 29-31]. In the present study, only two
patients (2.2%) had RBBB. Similarly, the prevalence
in former studies varied from 1.1% [32, 33] to 33%
[34, 35]. It was previously reported that the rates of
conduction disturbances varied according to the
disease duration but occurred among all ages [23,
28, 29, 32]. Moreover, it was mentioned that HLAB27 was strongly associated with conduction disturbances even in the absence of SpA and higher
disease activity [16, 29, 36].
Myocardial dysfunction and pericarditis can occur
among SpA patients but remain uncommon [15, 32,
37-39]. In our study, 3.3% of our patients had pericarditis whereas prevalence rates reported in former
studies were lower [31].
Multivariate logistic regression analysis identiﬁed
SpA-related EAMs as an independent predictive
factor for the development of cardiac involvement
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(OR ¼ 6.05; 95% CI: 1.197-30.607, p ¼ 0.029). This
could provide an insight on how the severity of SpA
could contribute to the development of cardiac
manifestations and prompt us to elaborate an
optimal management of SpA and its EAMs. In
several studies, age and disease duration were
associated with cardiac manifestations [24, 26].
Furthermore, the presence of peripheral arthritis
(other than hip and shoulder involvement)
increased the risk for cardiac abnormalities [17, 29].
No signiﬁcant difference was found between the last
cited parameters and the cardiac involvement in our
study.
In this cross-sectional study, there was no association between SpA treatment and heart involvement. This aspect could make the subject of a future
prospective study.

5. Conclusion
SpA and its EAMs increase the risk of cardiac
involvement. This must motivate clinical awareness
and needs a tight collaboration between rheumatologists and cardiologists to elaborate targeted
screening approaches for this risk group. Indeed, an
early diagnosis, the determination of the early therapeutic response and its monitoring have become
more and more important due to the availability of
effective therapies, especially biotherapies.
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